IL1B and atherosclerosis: Indeed, the Canakinumab Antiinflammatory Thrombosis Outcome Study trial demonstrated the clinical benefit of IL-1β blockade for cardiovascular risk.150 Interestingly, increased expression of Il1b in the bone marrow of mice trained with β-glucan was significantly reduced in animals lacking Set7, suggesting a role for this KMT in the long-term activation of trained immunity.116 Further exploration of metaboloepigenetic changes in endogenous trained immunity could yield novel approaches to interfere with the development and progression of atherosclerosis.